ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 128

Inhibition of Prolyl-tRNA Synthetase As a Novel Therapeutic Target for Systemic Sclerosis

Caroline H. Lee1, Seong-Jin Yoon1, Minjae Cho1, Joon Seok Park2, Yena Kim3, Ji Hyeon Ju4, Da-Jeong Bae5, Choon-Sik Park5, Jong Hyun Kim6, Sunghoon Kim6 and Bongyong Lee1, 1Daewoong Pharmaceuticals, Seoul, Korea, Republic of (South), 2Daewoong pharmaceutical, Seoul, Korea, Republic of (South), 3Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine,, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), 5Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Seoul, Korea, Republic of (South), 6Medicinal Bioconvergence Research Center, Seoul National University, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: fibrosis and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Prolyl-tRNA synthetase (PRS), a member of aminoacyl tRNA synthetases (ARS), is an enzyme that conjugates amino acid proline to its tRNA to generate prolyl-tRNA to be used in protein synthesis. Since proline is one of major components of collagen, we hypothesized that suppression of PRS would down-regulate collagen synthesis, which could be beneficial in fibrosis. Systemic sclerosis (SSc) is an autoimmune disease that is characterized by progressive thickening of skin, caused by excessive accumulation of collagen.

Methods:

Inhibitory activity of DWN12088 against PRS was assessed by aminoacylation assay. Fibroblasts were treated with DWN12088 either before or after treatment of transforming growth factor beta (TGFβ), and then collagen and pro-fibrotic markers were assessed using western blot. 3D skin organoid was constructed using systemic sclerosis patient-derived dermal fibroblast and keratinocyte. For in vivo study, constructed patient-derived 3D skin organoid was engrafted to SCID mouse using tie-over dressing. After 2 weeks administration of DWN12088, degree of dermal thickness and collagen I (Col I) expression were determined by histological analysis.

Results:

To validate our hypothesis, we investigated the expression levels of pro-fibrotic markers by overexpression or knockdown of PRS in vitro. We showed that PRS is closely related to the expression of Col I and alpha smooth muscle actin (αSMA). Interestingly, PRS protein expression is significantly increased in lung tissue of idiopathic pulmonary fibrosis (IPF) patients. We developed a novel selective inhibitor of PRS, DWN12088, which has IC50 value of 74 nM against PRS. DWN12088 reduced TGFβ-induced Col I and pro-fibrotic marker expression in various cell-lines and primary fibroblasts. This suggests that PRS may be a critical contributor of excessive accumulation of collagen, a main pathological hallmark of fibrosis.

Using systemic sclerosis patient-derived dermal fibroblast, we developed 3D skin organoid in order to investigate efficacy of DWN12088. In this model, DWN12088 successfully decreased skin thickness, Col I, and αSMA. In a mouse xenograft model using the patient-derived 3D skin organoid, treatment of 10 mg/kg DWN12088 also showed decrease in skin thickness and collagen expression compared to control group.

Conclusion:

PRS is an enzyme required during protein translation involving proline amino acid. In fibrotic condition, we observed that PRS is overexpressed, which may be responsible for over-production of collagen. Inhibition of PRS successfully inhibited formation of collagen and expression of pro-fibrotic markers in various cellular systems, systemic sclerosis patient-derived skin organoid model, and its mouse xenograft model. Therefore, DWN12088, a novel PRS inhibitor, may serve as a potential therapeutic agent in systemic sclerosis and other fibrotic diseases.


Disclosure: C. H. Lee, Daewoong Pharmaceuticals, 3; S. J. Yoon, Daewoong Pharmaceuticals, 3; M. Cho, Daewoong Pharmaceuticals, 3; J. S. Park, Daewoong Pharmaceuticals, 3; Y. Kim, None; J. H. Ju, None; D. J. Bae, None; C. S. Park, None; J. H. Kim, None; S. Kim, None; B. Lee, Daewoong Pharmaceuticals, 3.

To cite this abstract in AMA style:

Lee CH, Yoon SJ, Cho M, Park JS, Kim Y, Ju JH, Bae DJ, Park CS, Kim JH, Kim S, Lee B. Inhibition of Prolyl-tRNA Synthetase As a Novel Therapeutic Target for Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/inhibition-of-prolyl-trna-synthetase-as-a-novel-therapeutic-target-for-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-prolyl-trna-synthetase-as-a-novel-therapeutic-target-for-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology